Sign in
Active, not recruitingNo phase

Effect of Probiotics on Insulin Sensitivity in Overweight and Obese Pregnancy

Key facts

Who runs it
Medical University of Vienna
Where
Austria1 site in 1 countryChoose a country to see its sites
Trial code
Status
Active, not recruiting
People taking part
40 people enrolled
Started
8 Oct 2024
Expected to end
Feb 2027
Type of study
Interventional, 2 groupsOne group gets no study treatment, for comparison.
Treatments tested
  • OMNi-BiOTiC® METAtox
Record updated
6 November 2026

Who can take part

Age
18 years to 50 years
Sex
Women only
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 12 criteriaShow less

Who can take part

  • Pregnant women aged 18 to 50 years
  • Gestational age 12+0 to 15+6 at inclusion
  • Preconceptional body mass index ≥25 kg/m2
  • Written informed consent

Who cannot take part

  • Any acute illness within 2 weeks prior to the study
  • Status post bariatric surgery
  • Preconceptional diabetes (type 1, type 2 or others)
  • Preconceptional endocrine disorder (Cushing Syndrome, M. Addison)
  • HIV or hepatitis infection
  • Current malignant tumors
  • Severe liver or kidney dysfunction
  • Participation in another interventional study

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The goal of this clinical trial is to learn if taking a probiotic supplement during pregnancy improves the body's response to insulin (insulin sensitivity) in pregnant women who were overweight or obese before pregnancy (body mass index ≥25 kg/m2). Reduced insulin sensitivity is common in these women and increases the risk of gestational diabetes mellitus and excessive fetal growth. Growing evidence suggests that the bacteria in the gut (gut microbiome) play a role in regulating blood sugar and insulin action.

Read full original descriptionShow less

The main questions it aims to answer are:

* Does a daily probiotic supplement improve insulin sensitivity in mid-pregnancy? * Does it affect blood sugar levels, insulin production, the development of gestational diabetes mellitus, fetal growth and the gut bacteria of mothers and newborns?

Participants will:

* Take one sachet of the probiotic OMNi-BiOTiC® METAtox twice daily from early pregnancy until delivery (probiotic group only) * Attend three study visits in early, mid and late pregnancy with blood tests, an oral glucose tolerance test (early and mid pregnancy), measurements of weight and blood pressure, and questionnaires on diet and physical activity * Wear a glucose sensor on the upper arm for 10 days after each visit * Provide stool samples at each visit and a first stool sample of their newborn * Have fetal growth checked by ultrasound and pregnancy and birth outcomes recorded

The 2 groups in the trial

  • Probiotic supplementationTreatment being tested

    Women with a preconceptional BMI ≥25 kg/m2 taking one sachet of OMNi-BiOTiC® METAtox twice a day starting from randomization (12+0 to 15+6 weeks of gestation) until delivery.

    Treatment: OMNi-BiOTiC® METAtox

  • ControlNo study treatment, for comparison

    Women with a preconceptional BMI ≥25 kg/m2 receiving standard prenatal care without probiotic supplementation.

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
To Assess the Possible Influence of Probiotics on Insulin Sensitivity in Overweight and Obese Pregnancy - a Pilot Study
Record updated
6 November 2026